Skip to main content
Top
Published in: Tumor Biology 3/2013

01-06-2013 | Research Article

Discussion of modifying stage IV gastric cancer based on Borrmann classification

Authors: Bin Yang, Guoqiang Wu, Xiaochen Wang, Xuefeng Zhang

Published in: Tumor Biology | Issue 3/2013

Login to get access

Abstract

This study aims to investigate the prognostic significance of reclassification of stage IV gastric cancers in conjunction with Borrmann type. A total of 1,673 gastric cancer patients who received a gastrectomy between 1980 and 2003 were retrospectively evaluated. Of the patients, 244 (14.58 %), 344 (20.56 %), 589 (35.21 %), and 496 (29.65 %) had stage I, II, III, and IV cancers, respectively. After Cox regression analysis, Borrmann type was identified to be the independent prognostic factor in stage IV gastric cancer. The disease-specific postoperative survival of patients with Borrmann I, II, and III tumors was clearly distinguished by TNM classification system (P < 0.05), while it failed to classify Borrmann IV tumors (P = 0.147). Interestingly, the disease-specific postoperative survival of stage IV patients with Borrmann IV tumors (group 1) was significantly poor than the cases with stage IV but not Borrmann IV tumors (group 2), as well as the patients with Borrmann IV while not included in stage IV tumors (group 3) (P = 0.022 and P = 0.000, respectively). Meanwhile, the disease-specific postoperative survival was not observed as significantly different between group 2 and group 3 (P = 0.063); furthermore, group 2 + 3 had a better prognosis than group 1 (introduced stage IVa vs. stage IVb; P = 0.006). Reclassification of stage IV through combining the present TNM classification system with Borrmann type may more accurately predict the prognosis of patients.
Literature
1.
go back to reference Shimoyama S, Seto Y, Yasuda H, Mafune K, Kaminishi M. Concepts, rationale, and current outcomes of less invasive surgical strategies for early gastric cancer: date from a quarter-century of experience in a single institution. World J Surg. 2005;29:58–65.PubMedCrossRef Shimoyama S, Seto Y, Yasuda H, Mafune K, Kaminishi M. Concepts, rationale, and current outcomes of less invasive surgical strategies for early gastric cancer: date from a quarter-century of experience in a single institution. World J Surg. 2005;29:58–65.PubMedCrossRef
2.
go back to reference Lindsey H. Preoperative chemoradiotherapy shows promise in gastric cancer. Lancet Oncol. 2004;5:519.PubMedCrossRef Lindsey H. Preoperative chemoradiotherapy shows promise in gastric cancer. Lancet Oncol. 2004;5:519.PubMedCrossRef
3.
go back to reference Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27(6):851–6.PubMedCrossRef Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27(6):851–6.PubMedCrossRef
4.
go back to reference Ohtsu A, Yoshida S, Sajio N. Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol. 2006;24:2188–96.PubMedCrossRef Ohtsu A, Yoshida S, Sajio N. Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol. 2006;24:2188–96.PubMedCrossRef
5.
go back to reference Adchi Y, Shiraishi N, Kitano S. Modern treatment of early gastric cancer: review of the Japanese experience. Dig Surg. 2002;19:333–9.CrossRef Adchi Y, Shiraishi N, Kitano S. Modern treatment of early gastric cancer: review of the Japanese experience. Dig Surg. 2002;19:333–9.CrossRef
6.
go back to reference Schwartz GK, Winter K, Minsky BD, Crane C, Thomson PJ, Anne P, et al. Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114). J Clin Oncol. 2009;27(12):1956–62.PubMedCrossRef Schwartz GK, Winter K, Minsky BD, Crane C, Thomson PJ, Anne P, et al. Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114). J Clin Oncol. 2009;27(12):1956–62.PubMedCrossRef
7.
go back to reference Küchler T, Bestmann B, Rappat S, Henne-Bruns D, Wood-Dauphinee S. Impact of psychotherapeutic support for patients with gastrointestinal cancer undergoing surgery: 10-year survival results of a randomized trial. J Clin Oncol. 2007;25(19):2702–8.PubMedCrossRef Küchler T, Bestmann B, Rappat S, Henne-Bruns D, Wood-Dauphinee S. Impact of psychotherapeutic support for patients with gastrointestinal cancer undergoing surgery: 10-year survival results of a randomized trial. J Clin Oncol. 2007;25(19):2702–8.PubMedCrossRef
8.
go back to reference Yamashita K, Sakuramoto S, Kikuchi S, Katada N, Kobayashi N, Watanabe M. Validation of staging systems for gastric cancer. Gastric Cancer. 2008;11(2):111–8.PubMedCrossRef Yamashita K, Sakuramoto S, Kikuchi S, Katada N, Kobayashi N, Watanabe M. Validation of staging systems for gastric cancer. Gastric Cancer. 2008;11(2):111–8.PubMedCrossRef
9.
go back to reference Hidaka H, Eto T, Maehara N, Jimi S, Hotokezaka M, Chijiiwa K. Comparative effect of lymph node metastasis classified by the anatomical site or by the number of nodes involved on prognosis of patients with gastric cancer. Hepatogastroenterology. 2008;55(88):2269–72.PubMed Hidaka H, Eto T, Maehara N, Jimi S, Hotokezaka M, Chijiiwa K. Comparative effect of lymph node metastasis classified by the anatomical site or by the number of nodes involved on prognosis of patients with gastric cancer. Hepatogastroenterology. 2008;55(88):2269–72.PubMed
10.
go back to reference Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. J Clin Oncol. 2005;23(28):7114–24.PubMedCrossRef Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. J Clin Oncol. 2005;23(28):7114–24.PubMedCrossRef
11.
go back to reference Tiberio GA, Coniglio A, Marchet A, Marrelli D, Giacopuzzi S, Baiocchi L, et al. Metachronous hepatic metastases from gastric carcinoma: a multicentric survey. Eur J Surg Oncol. 2009;35(5):486–91.PubMedCrossRef Tiberio GA, Coniglio A, Marchet A, Marrelli D, Giacopuzzi S, Baiocchi L, et al. Metachronous hepatic metastases from gastric carcinoma: a multicentric survey. Eur J Surg Oncol. 2009;35(5):486–91.PubMedCrossRef
12.
go back to reference Huang B, Zheng X, Wang Z, Wang M, Dong Y, Zhao B, et al. Prognostic significance of the number of metastatic lymph nodes: is UICC/TNM node classification perfectly suitable for early gastric cancer? Ann Surg Oncol. 2009;16(1):61–7.PubMedCrossRef Huang B, Zheng X, Wang Z, Wang M, Dong Y, Zhao B, et al. Prognostic significance of the number of metastatic lymph nodes: is UICC/TNM node classification perfectly suitable for early gastric cancer? Ann Surg Oncol. 2009;16(1):61–7.PubMedCrossRef
13.
go back to reference Nitti D, Marchet A, Mocellin S, Rossi GM, Ambrosi A, Mencarelli R. Prognostic value of subclassification of T2 tumours in patients with gastric cancer. Br J Surg. 2009;96(4):398–404.PubMedCrossRef Nitti D, Marchet A, Mocellin S, Rossi GM, Ambrosi A, Mencarelli R. Prognostic value of subclassification of T2 tumours in patients with gastric cancer. Br J Surg. 2009;96(4):398–404.PubMedCrossRef
14.
go back to reference Sun Z, Zhu GL, Lu C, Guo PT, Huang BJ, Li K, et al. A novel subclassification of pT2 gastric cancers according to the depth of muscularis propria invasion: superficial muscularis propria versus deep muscularis propria/subserosa. Ann Surg. 2009;249(5):768–75.PubMedCrossRef Sun Z, Zhu GL, Lu C, Guo PT, Huang BJ, Li K, et al. A novel subclassification of pT2 gastric cancers according to the depth of muscularis propria invasion: superficial muscularis propria versus deep muscularis propria/subserosa. Ann Surg. 2009;249(5):768–75.PubMedCrossRef
15.
go back to reference Kim DH, Oh CA, Oh SJ, Choi MG, Noh JH, Sohn TS, et al. Validation of seventh edition AJCC gastric cancer staging modifications. J Surg Oncol. 2012;105(1):26–30.PubMedCrossRef Kim DH, Oh CA, Oh SJ, Choi MG, Noh JH, Sohn TS, et al. Validation of seventh edition AJCC gastric cancer staging modifications. J Surg Oncol. 2012;105(1):26–30.PubMedCrossRef
16.
go back to reference Chen CY, Wu CW, Lo SS, Hsieh MC, Lui WY, Shen KH. Peritoneal carcinomatosis and lymph node metastasis are prognostic indicators in patients with Borrmann type IV gastric carcinoma. Hepatogastroenterology. 2002;49(45):874–7.PubMed Chen CY, Wu CW, Lo SS, Hsieh MC, Lui WY, Shen KH. Peritoneal carcinomatosis and lymph node metastasis are prognostic indicators in patients with Borrmann type IV gastric carcinoma. Hepatogastroenterology. 2002;49(45):874–7.PubMed
17.
go back to reference Kim DY, Kim HR, Kim YJ, Kim S. Clinicopathological features of patients with Borrmann type IV gastric carcinoma. ANZ J Surg. 2002;72(10):739–42.PubMedCrossRef Kim DY, Kim HR, Kim YJ, Kim S. Clinicopathological features of patients with Borrmann type IV gastric carcinoma. ANZ J Surg. 2002;72(10):739–42.PubMedCrossRef
18.
go back to reference An JY, Kang TH, Choi MG, Noh JH, Sohn TS, et al. Borrmann type IV: an independent prognostic factor for survival in gastric cancer. J Gastrointest Surg. 2008;12(8):1364–9.PubMedCrossRef An JY, Kang TH, Choi MG, Noh JH, Sohn TS, et al. Borrmann type IV: an independent prognostic factor for survival in gastric cancer. J Gastrointest Surg. 2008;12(8):1364–9.PubMedCrossRef
19.
go back to reference International Union Against Cancer. In: Sobin LH, Wittekind CH, editors. TNM classification of malignant tumors. 5th ed. New York: Wiley; 1997. International Union Against Cancer. In: Sobin LH, Wittekind CH, editors. TNM classification of malignant tumors. 5th ed. New York: Wiley; 1997.
20.
go back to reference Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma. 2nd English edition. Gastric Cancer. 1998;1:10–24.PubMedCrossRef Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma. 2nd English edition. Gastric Cancer. 1998;1:10–24.PubMedCrossRef
21.
go back to reference Teramoto K, Tada M, Tamoto E, Abe M, Kawakami A, Komuro K, et al. Prediction of lymphatic invasion/lymph node metastasis, recurrence, and survival in patients with gastric cancer by cDNA array-based expression profiling. J Surg Res. 2005;124:225–36.PubMedCrossRef Teramoto K, Tada M, Tamoto E, Abe M, Kawakami A, Komuro K, et al. Prediction of lymphatic invasion/lymph node metastasis, recurrence, and survival in patients with gastric cancer by cDNA array-based expression profiling. J Surg Res. 2005;124:225–36.PubMedCrossRef
22.
go back to reference Rabin I, Chikman B, Lavy R, Sandbank J, Maklakovsky M, Gold-Deutch R, et al. Gastrointestinal stromal tumors: a 19 year experience. Isr Med Assoc J. 2009;11(2):98–102.PubMed Rabin I, Chikman B, Lavy R, Sandbank J, Maklakovsky M, Gold-Deutch R, et al. Gastrointestinal stromal tumors: a 19 year experience. Isr Med Assoc J. 2009;11(2):98–102.PubMed
23.
go back to reference An JY, Ha TK, Noh JH, Sohn TS, Kim S. Proposal to subclassify stage IV gastric cancer into IVA, IVB, and IVM. Arch Surg. 2009;144(1):38–45. discussion 45.PubMedCrossRef An JY, Ha TK, Noh JH, Sohn TS, Kim S. Proposal to subclassify stage IV gastric cancer into IVA, IVB, and IVM. Arch Surg. 2009;144(1):38–45. discussion 45.PubMedCrossRef
24.
go back to reference Li C, Yan M, Chen J, Xiang M, Zhu ZG, Lin YZ. Prognostic influence of sub-stages according to pTNM categories in patients with stage IV gastric cancer. J Surg Oncol. 2009;99(6):324–8.PubMedCrossRef Li C, Yan M, Chen J, Xiang M, Zhu ZG, Lin YZ. Prognostic influence of sub-stages according to pTNM categories in patients with stage IV gastric cancer. J Surg Oncol. 2009;99(6):324–8.PubMedCrossRef
Metadata
Title
Discussion of modifying stage IV gastric cancer based on Borrmann classification
Authors
Bin Yang
Guoqiang Wu
Xiaochen Wang
Xuefeng Zhang
Publication date
01-06-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 3/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0673-7

Other articles of this Issue 3/2013

Tumor Biology 3/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine